{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T11:04:08Z","timestamp":1789902248157,"version":"4.0.1"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.phrs.2026.108382","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T07:08:19Z","timestamp":1786518499000},"page":"108382","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs"],"prefix":"10.1016","volume":"232","author":[{"given":"Sophia L.","family":"Fischer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9438-695X","authenticated-orcid":false,"given":"Tito","family":"Borner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2026.108382_bib1","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1053\/j.gastro.2007.03.052","article-title":"The epidemiology of obesity","volume":"132","author":"Ogden","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2026.108382_bib2","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s40273-014-0230-2","article-title":"Savings in medical expenditures associated with reductions in body mass index among US adults with obesity, by diabetes status","volume":"33","author":"Cawley","year":"2015","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.phrs.2026.108382_bib3","first-page":"354","article-title":"Direct medical costs of obesity in the United States and the most populous states","volume":"27","author":"Cawley","year":"2021","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.phrs.2026.108382_bib4","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(25)00355-1","article-title":"Global, regional, and national prevalence of adult overweight and obesity, 1990\u20132021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021","volume":"405","author":"Ng","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2026.108382_bib5","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.phrs.2026.108382_bib6","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2026.108382_bib7","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1111\/dom.16176","article-title":"Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the <scp>SURMOUNT<\/scp> -1 to -4 trials","volume":"27","author":"Rubino","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2026.108382_bib8","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/dom.14551","article-title":"Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss","volume":"24","author":"Wharton","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2026.108382_bib9","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1002\/oby.70058","article-title":"Reasons for discontinuation of obesity pharmacotherapy with semaglutide or tirzepatide in clinical practice","volume":"33","author":"Gasoyan","year":"2025","journal-title":"Obesity"},{"key":"10.1016\/j.phrs.2026.108382_bib10","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJMoa2502081","article-title":"Coadministered cagrilintide and semaglutide in adults with overweight or obesity","volume":"393","author":"Garvey","year":"2025","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.phrs.2026.108382_bib11","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/S0140-6736(25)02155-5","article-title":"Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial","volume":"406","author":"Billings","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2026.108382_bib12","doi-asserted-by":"crossref","first-page":"11688","DOI":"10.1021\/acs.jmedchem.4c00022","article-title":"NN1213 \u2013 A potent, long-acting, and selective analog of human amylin","volume":"67","author":"Dahl","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.108382_bib13","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s42255-026-01465-4","article-title":"The story of amylin: from physiology to therapy","volume":"8","author":"Secher","year":"2026","journal-title":"Nat. Metab."},{"key":"10.1016\/j.phrs.2026.108382_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2025.110587","article-title":"Role of amylin in feeding and satiation","volume":"278","author":"Lutz","year":"2025","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2026.108382_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101444","article-title":"Hypophagia induced by salmon calcitonin, but not by amylin, is partially driven by malaise and is mediated by CGRP neurons","volume":"58","author":"Boccia","year":"2022","journal-title":"Mol. Metab."},{"key":"10.1016\/j.phrs.2026.108382_bib16","doi-asserted-by":"crossref","first-page":"R114","DOI":"10.1152\/ajpregu.00333.2003","article-title":"The anorectic hormone amylin contributes to feeding-related changes of neuronal activity in key structures of the gut-brain axis","volume":"286","author":"Riediger","year":"2004","journal-title":"Am. J. Physiol. -Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.phrs.2026.108382_bib17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.physbeh.2014.01.013","article-title":"Amylin activates distributed CNS nuclei to control energy balance","volume":"136","author":"Mietlicki-Baase","year":"2014","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.phrs.2026.108382_bib18","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0196-9781(97)00292-1","article-title":"Lesion of the area postrema\/nucleus of the solitary tract (AP\/NTS) attenuates the anorectic effects of amylin and calcitonin gene-related peptide (CGRP) in Rats","volume":"19","author":"Lutz","year":"1998","journal-title":"Pept. (N. Y. )."},{"key":"10.1016\/j.phrs.2026.108382_bib19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.brainres.2003.10.040","article-title":"Peripheral amylin activates circumventricular organs expressing calcitonin receptor a\/b subtypes and receptor-activity modifying proteins in the rat","volume":"997","author":"Barth","year":"2004","journal-title":"Brain Res."},{"key":"10.1016\/j.phrs.2026.108382_bib20","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/bcpt.13427","article-title":"Central control of energy balance by amylin and calcitonin receptor agonists and their potential for treatment of metabolic diseases","volume":"127","author":"Zakariassen","year":"2020","journal-title":"Basic. Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.phrs.2026.108382_bib21","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.cmet.2012.06.015","article-title":"Hindbrain neurons as an essential hub in the neuroanatomically distributed control of energy balance","volume":"16","author":"Grill","year":"2012","journal-title":"Cell. Metab."},{"key":"10.1016\/j.phrs.2026.108382_bib22","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1177\/1073858407311100","article-title":"The area postrema: a brain monitor and integrator of systemic autonomic state","volume":"14","author":"Price","year":"2008","journal-title":"Neuroscientist"},{"key":"10.1016\/j.phrs.2026.108382_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2020.170366","article-title":"Amylin brain circuitry","volume":"132","author":"Boccia","year":"2020","journal-title":"Peptides"},{"key":"10.1016\/j.phrs.2026.108382_bib24","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1038\/npp.2013.66","article-title":"Amylin receptor signaling in the ventral tegmental area is physiologically relevant for the control of food intake","volume":"38","author":"Mietlicki-Baase","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.phrs.2026.108382_bib25","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/0024-3205(95)02197-Q","article-title":"Permeability of the blood-brain barrier to amylin","volume":"57","author":"Banks","year":"1995","journal-title":"Life Sci."},{"key":"10.1016\/j.phrs.2026.108382_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.107987","article-title":"Salmon calcitonin distributes into the arcuate nucleus to a subset of NPY neurons in mice","volume":"167","author":"Zakariassen","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2026.108382_bib27","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1476-5381.2011.01717.x","article-title":"Pharmacological characterization of rat amylin receptors: implications for the identification of amylin receptor subtypes","volume":"166","author":"Bailey","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2026.108382_bib28","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1111\/bph.13496","article-title":"Amylin structure\u2013function relationships and receptor pharmacology: implications for amylin mimetic drug development","volume":"173","author":"Bower","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2026.108382_bib29","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1042\/BST20150237","article-title":"Receptor activity-modifying proteins; multifunctional G protein-coupled receptor accessory proteins","volume":"44","author":"Hay","year":"2016","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.phrs.2026.108382_bib30","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1124\/mol.104.008615","article-title":"Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes","volume":"67","author":"Hay","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.phrs.2026.108382_bib31","article-title":"A structural basis for amylin receptor phenotype","volume":"375","author":"Cao","year":"2022","journal-title":"Science (1979)"},{"key":"10.1016\/j.phrs.2026.108382_bib32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bph.14075","article-title":"Update on the pharmacology of calcitonin\/CGRP family of peptides: IUPHAR Review 25","volume":"175","author":"Hay","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2026.108382_bib33","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.2337\/db10-0692","article-title":"Neuronal receptor activity\u2013modifying protein 1 promotes energy expenditure in mice","volume":"60","author":"Zhang","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.phrs.2026.108382_bib34","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.neuroscience.2019.11.036","article-title":"RAMP1 and RAMP3 differentially control amylin\u2019s effects on food intake, glucose and energy balance in male and female mice","volume":"447","author":"Coester","year":"2020","journal-title":"Neuroscience"},{"key":"10.1016\/j.phrs.2026.108382_bib35","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1210\/me.2010-0400","article-title":"Research Resource: haploinsufficiency of receptor activity-modifying protein-2 (Ramp2) causes reduced fertility, hyperprolactinemia, skeletal abnormalities, and endocrine dysfunction in mice","volume":"25","author":"Kadmiel","year":"2011","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.phrs.2026.108382_bib36","doi-asserted-by":"crossref","first-page":"18094","DOI":"10.1074\/jbc.M703544200","article-title":"Receptor activity-modifying proteins 2 and 3 have distinct physiological functions from embryogenesis to old age","volume":"282","author":"Dackor","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2026.108382_bib37","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1139\/y95-146","article-title":"Comparative distribution of receptors for amylin and the related peptides calcitonin gene related peptide and calcitonin in rat and monkey brain","volume":"73","author":"Christopoulos","year":"1995","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.phrs.2026.108382_bib38","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0026-895X(25)13212-4","article-title":"High affinity amylin binding sites in rat brain","volume":"44","author":"Beaumont","year":"1993","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.phrs.2026.108382_bib39","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/ejn.13163","article-title":"Amylin receptor components and the leptin receptor are co-expressed in single rat area postrema neurons","volume":"43","author":"Liberini","year":"2016","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.phrs.2026.108382_bib40","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/s42255-026-01539-3","article-title":"A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance","volume":"8","author":"Ludwig","year":"2026","journal-title":"Nat. Metab."},{"key":"10.1016\/j.phrs.2026.108382_bib41","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/0306-4522(94)90388-3","article-title":"vitro autoradiographic localization of amylin binding sites in rat brain","volume":"62","author":"Sexton","year":"1994","journal-title":"Neuroscience"},{"key":"10.1016\/j.phrs.2026.108382_bib42","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.physbeh.2017.03.023","article-title":"The area postrema (AP) and the parabrachial nucleus (PBN) are important sites for salmon calcitonin (sCT) to decrease evoked phasic dopamine release in the nucleus accumbens (NAc)","volume":"176","author":"Whiting","year":"2017","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.phrs.2026.108382_bib43","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/j.1552-4604.1996.tb04147.x","article-title":"Pharmacokinetics and Pharmacodynamics of AC137 (25,28,29 Tripro-Amylin, Human) after intravenous bolus and infusion doses in patients with insulin-dependent diabetes","volume":"36","author":"Colburn","year":"1996","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2026.108382_bib44","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/(SICI)1098-2299(199604)37:4<231::AID-DDR5>3.0.CO;2-M","article-title":"Preclinical pharmacology of pramlintide in the rat: Comparisons with human and rat amylin","volume":"37","author":"Young","year":"1996","journal-title":"Drug. Dev. Res."},{"key":"10.1016\/j.phrs.2026.108382_bib45","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1210\/en.2013-1658","article-title":"Activity of pramlintide, rat and human amylin but not A\u03b21-42 at human amylin receptors","volume":"155","author":"Gingell","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.phrs.2026.108382_bib46","doi-asserted-by":"crossref","first-page":"8686","DOI":"10.1074\/jbc.M115.713628","article-title":"Calcitonin and Amylin Receptor Peptide Interaction Mechanisms: insights into peptide-binding modes and allosteric modulation of the calcitonin receptor by receptor activity-modifying proteins","volume":"291","author":"Lee","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2026.108382_bib47","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.2337\/dc07-0589","article-title":"Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin","volume":"30","author":"Riddle","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2026.108382_bib48","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/j.1464-5491.2004.01319.x","article-title":"Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial","volume":"21","author":"Ratner","year":"2004","journal-title":"Diabet. Med."},{"key":"10.1016\/j.phrs.2026.108382_bib49","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1210\/jc.2006-2003","article-title":"Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study","volume":"92","author":"Aronne","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2026.108382_bib50","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s00125-005-1732-4","article-title":"Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes","volume":"48","author":"Chapman","year":"2005","journal-title":"Diabetologia"},{"key":"10.1016\/j.phrs.2026.108382_bib51","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1007\/s12325-016-0326-5","article-title":"Impact of disease duration on the effects of pramlintide in type 1 diabetes: a post hoc analysis of three clinical trials","volume":"33","author":"Herrmann","year":"2016","journal-title":"Adv. Ther."},{"key":"10.1016\/j.phrs.2026.108382_bib52","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1124\/jpet.121.000567","article-title":"AM833 is a novel agonist of calcitonin family g protein\u2013coupled receptors: pharmacological comparison with six selective and nonselective agonists","volume":"377","author":"Fletcher","year":"2021","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2026.108382_bib53","doi-asserted-by":"crossref","first-page":"11183","DOI":"10.1021\/acs.jmedchem.1c00565","article-title":"Development of cagrilintide, a long-acting amylin analogue","volume":"64","author":"Kruse","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.108382_bib54","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(21)00845-X","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2\u00b74 mg for weight management: a randomised, controlled, phase 1b trial","volume":"397","author":"Enebo","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2026.108382_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113842","article-title":"Does receptor balance matter? \u2013 Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models","volume":"156","author":"Larsen","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.phrs.2026.108382_bib56","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/s42255-025-01324-8","article-title":"CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure","volume":"7","author":"Jacobsen","year":"2025","journal-title":"Nat. Metab."},{"key":"10.1016\/j.phrs.2026.108382_bib57","doi-asserted-by":"crossref","first-page":"R605","DOI":"10.1152\/ajpregu.2001.280.3.R605","article-title":"Comparative effects of amylin and cholecystokinin on food intake and gastric emptying in rats","volume":"280","author":"Reidelberger","year":"2001","journal-title":"Am. J. Physiol. -Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.phrs.2026.108382_bib58","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","article-title":"Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial","volume":"398","author":"Lau","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2026.108382_bib59","doi-asserted-by":"crossref","first-page":"23925","DOI":"10.1021\/acs.jmedchem.5c01185","article-title":"Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue","volume":"68","author":"Fischer Munch","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2026.108382_bib60","doi-asserted-by":"crossref","DOI":"10.1111\/dom.70753","article-title":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials","author":"Br\u00e6ndholt Olsen","year":"2026","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2026.108382_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2025.102271","article-title":"Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept","volume":"102","author":"Briere","year":"2025","journal-title":"Mol. Metab."},{"key":"10.1016\/j.phrs.2026.108382_bib62","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1111\/dom.70439","article-title":"Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept","volume":"28","author":"Bhattachar","year":"2026","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2026.108382_bib63","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0140-6736(25)01185-7","article-title":"Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b\/2a randomised controlled study","volume":"406","author":"Dahl","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2026.108382_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105862","article-title":"The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats","volume":"118","author":"Kuhre","year":"2025","journal-title":"EBioMedicine"},{"key":"10.1016\/j.phrs.2026.108382_bib65","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0140-6736(25)01176-6","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial","volume":"406","author":"Gasiorek","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2026.108382_bib66","doi-asserted-by":"crossref","DOI":"10.2337\/db25-88-OR","article-title":"88-OR: Long-Acting Amylin Analog AZD6234 in Combination with the GLP-1R agonist semaglutide enhances body weight and fat mass loss in diet-induced obese (DIO) Rats","volume":"74","author":"Geoghegan","year":"2025","journal-title":"Diabetes"},{"key":"10.1016\/j.phrs.2026.108382_bib67","article-title":"Characterisation of AZD6234, a novel amylin receptor selective agonist peptide, in rodent models of weight loss and aversion","volume":"68","author":"Hornigold","year":"2025","journal-title":"Diabetologica"},{"key":"10.1016\/j.phrs.2026.108382_bib68","unstructured":"AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity. https:\/\/news.abbvie.com\/2025-03-03-AbbVie-and-Gubra-Announce-License-Agreement-to-Develop-an-Amylin-Analog-for-the-Treatment-of-Obesity? (2025)."},{"key":"10.1016\/j.phrs.2026.108382_bib69","unstructured":"Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity. https:\/\/ir.structuretx.com\/news-releases\/news-release-details\/structure-therapeutics-announces-initiation-phase-1-clinical (2025)."},{"key":"10.1016\/j.phrs.2026.108382_bib70","unstructured":"Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity. https:\/\/ir.structuretx.com\/news-releases\/news-release-details\/structure-therapeutics-announces-selection-lead-oral-small (2024)."},{"key":"10.1016\/j.phrs.2026.108382_bib71","article-title":"Central mechanisms of emesis: A role for GDF15","volume":"37","author":"Borner","year":"2024","journal-title":"Neurogastroenterol. & Motil."},{"key":"10.1016\/j.phrs.2026.108382_bib72","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejphar.2013.08.047","article-title":"The role of vagal neurocircuits in the regulation of nausea and vomiting","volume":"722","author":"Babic","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2026.108382_bib73","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133429","article-title":"Semaglutide lowers body weight in rodents via distributed neural pathways","volume":"5","author":"Gabery","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.phrs.2026.108382_bib74","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/dom.14663","article-title":"Growth differentiation factor 15 and semaglutide inhibit food intake and body weight through largely distinct, additive mechanisms","volume":"24","author":"Ghidewon","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2026.108382_bib75","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/bph.15647","article-title":"Glucagon-like peptide-1 in diabetes care: can glycaemic control be achieved without nausea and vomiting?","volume":"179","author":"Borner","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2026.108382_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107543","article-title":"GDF15 induces an aversive visceral malaise state that drives anorexia and weight loss","volume":"31","author":"Borner","year":"2020","journal-title":"Cell. Rep."},{"key":"10.1016\/j.phrs.2026.108382_bib77","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/0031-9384(95)02067-5","article-title":"Amylin decreases meal size in rats","volume":"58","author":"Lutz","year":"1995","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.phrs.2026.108382_bib78","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/0196-9781(92)90057-A","article-title":"Tests of adipsia and conditioned taste aversion following the intrahypothalamic injection of amylin","volume":"13","author":"Chance","year":"1992","journal-title":"Peptides"},{"key":"10.1016\/j.phrs.2026.108382_bib79","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0196-9781(02)00022-0","article-title":"Acute 3rd-ventricular amylin infusion potently reduces food intake but does not produce aversive consequences","volume":"23","author":"Rushing","year":"2002","journal-title":"Peptides"},{"key":"10.1016\/j.phrs.2026.108382_bib80","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.2337\/db21-0459","article-title":"GIP Receptor Agonism Attenuates GLP-1 receptor agonist\u2013induced nausea and emesis in preclinical models","volume":"70","author":"Borner","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.phrs.2026.108382_bib81","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.physbeh.2013.02.006","article-title":"Amylin and GLP-1 target different populations of area postrema neurons that are both modulated by nutrient stimuli","volume":"112\u2013113","author":"Z\u00fcger","year":"2013","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.phrs.2026.108382_bib82","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s42255-021-00363-1","article-title":"A genetic map of the mouse dorsal vagal complex and its role in obesity","volume":"3","author":"Ludwig","year":"2021","journal-title":"Nat. Metab."},{"key":"10.1016\/j.phrs.2026.108382_bib83","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.neuron.2020.11.010","article-title":"Area postrema cell types that mediate nausea-associated behaviors","volume":"109","author":"Zhang","year":"2021","journal-title":"Neuron"},{"key":"10.1016\/j.phrs.2026.108382_bib84","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.cmet.2019.12.012","article-title":"Calcitonin receptor neurons in the mouse nucleus tractus solitarius control energy balance via the non-aversive suppression of feeding","volume":"31","author":"Cheng","year":"2020","journal-title":"Cell. Metab."},{"key":"10.1016\/j.phrs.2026.108382_bib85","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.cmet.2016.04.006","article-title":"Parabrachial CGRP Neurons Control Meal Termination","volume":"23","author":"Campos","year":"2016","journal-title":"Cell. Metab."},{"key":"10.1016\/j.phrs.2026.108382_bib86","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.tins.2018.03.007","article-title":"The parabrachial nucleus: CGRP neurons function as a general alarm","volume":"41","author":"Palmiter","year":"2018","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.phrs.2026.108382_bib87","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41580-018-0049-3","article-title":"Mechanisms of signalling and biased agonism in G protein-coupled receptors","volume":"19","author":"Wootten","year":"2018","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"10.1016\/j.phrs.2026.108382_bib88","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/bph.15497","article-title":"The therapeutic potential of GLP-1 receptor biased agonism","volume":"179","author":"Jones","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2026.108382_bib89","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217458","article-title":"Conditioned taste aversion versus avoidance: A re-examination of the separate processes hypothesis","volume":"14","author":"Schier","year":"2019","journal-title":"PLoS. One"},{"key":"10.1016\/j.phrs.2026.108382_bib90","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0006-8993(78)90568-1","article-title":"The taste reactivity test. I. Mimetic responses to gustatory stimuli in neurologically normal rats","volume":"143","author":"Grill","year":"1978","journal-title":"Brain Res."},{"key":"10.1016\/j.phrs.2026.108382_bib91","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adu1589","article-title":"Hypophagia and body weight loss by tirzepatide are accompanied by fewer GI adverse events compared to semaglutide in preclinical models","volume":"11","author":"Borner","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.phrs.2026.108382_bib92","doi-asserted-by":"crossref","first-page":"R1855","DOI":"10.1152\/ajpregu.00297.2007","article-title":"Pharmacological actions of the peptide hormone amylin in the long-term regulation of food intake, food preference, and body weight","volume":"293","author":"Mack","year":"2007","journal-title":"Am. J. Physiol. -Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.phrs.2026.108382_bib93","doi-asserted-by":"crossref","first-page":"4863","DOI":"10.1111\/ejn.15376","article-title":"A selective role for receptor activity-modifying proteins in subchronic action of the amylin selective receptor agonist NN1213 compared with salmon calcitonin on body weight and food intake in male mice","volume":"54","author":"Arrigoni","year":"2021","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.phrs.2026.108382_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2025.105836","article-title":"Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3","volume":"118","author":"Carvas","year":"2025","journal-title":"EBioMedicine"},{"key":"10.1016\/j.phrs.2026.108382_bib95","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s11154-025-09967-4","article-title":"New drugs for the treatment of obesity: do we need approaches to preserve muscle mass?","volume":"26","author":"Ryan","year":"2025","journal-title":"Rev. Endocr. Metab. Disord."},{"issue":"4","key":"10.1016\/j.phrs.2026.108382_bib96","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies","volume":"26","author":"Neeland","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2026.108382_bib97","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00592-025-02611-2","article-title":"Muscle loss and GLP-1R agonists use","volume":"63","author":"Rossi","year":"2025","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.phrs.2026.108382_bib98","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1080\/14656566.2024.2343092","article-title":"A systematic review of the effect of semaglutide on lean mass: insights from clinical trials","volume":"25","author":"Bikou","year":"2024","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.phrs.2026.108382_bib99","doi-asserted-by":"crossref","DOI":"10.1111\/bph.70484","article-title":"Amylin analogues as a novel perspective in anti-obesity therapy","author":"Lutz","year":"2026","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2026.108382_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2025.123845","article-title":"Characterization of 0839 \u2013 A tool compound for pre-clinical mode-of-action studies of amylin analogues such as cagrilintide","volume":"378","author":"Gabery","year":"2025","journal-title":"Life Sci."},{"key":"10.1016\/j.phrs.2026.108382_bib101","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1007\/BF02561371","article-title":"Use of nasally administered salmon calcitonin in preventing bone loss","volume":"49","author":"Christiansen","year":"1991","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.phrs.2026.108382_bib102","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1517\/14712598.2010.526104","article-title":"Oral salmon calcitonin \u2013 pharmacology in osteoporosis","volume":"10","author":"Henriksen","year":"2010","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.phrs.2026.108382_bib103","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jsbmb.2013.09.008","article-title":"Prevention and treatment of postmenopausal osteoporosis","volume":"142","author":"Tella","year":"2014","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.phrs.2026.108382_bib104","doi-asserted-by":"crossref","first-page":"4827","DOI":"10.3390\/ijms25094827","article-title":"Links among Obesity, Type 2 Diabetes Mellitus, and Osteoporosis: Bone as a Target","volume":"25","author":"Martiniakova","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2026.108382_bib105","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/bph.12129","article-title":"CGRP in the trigeminovascular system: a role CGRP, adrenomedullin and amylin receptors?","volume":"170","author":"Walker","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2026.108382_bib106","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/ana.26072","article-title":"Amylin analog pramlintide induces migraine-like attacks in patients","volume":"89","author":"Ghanizada","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.phrs.2026.108382_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 receptor agonists","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2026.108382_bib108","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.cmet.2024.05.001","article-title":"Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule","volume":"36","author":"Ben Nasr","year":"2024","journal-title":"Cell. Metab."},{"key":"10.1016\/j.phrs.2026.108382_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopsych.2026.06.006","article-title":"Glucagon-like peptide-1 signaling in learning and memory: evidence, mechanisms, and therapeutic implications","author":"Bashaw","year":"2026","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2026.108382_bib110","doi-asserted-by":"crossref","DOI":"10.1002\/cph4.70129","article-title":"GLP-1 at the Metabolic\u2013Cognitive Interface: Reward, Affect, and Memory","volume":"16","author":"Gao","year":"2026","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.phrs.2026.108382_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.108036","article-title":"Psychotropic effects of GLP-1R agonists","volume":"222","author":"Bucciarelli","year":"2025","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2026.108382_bib112","doi-asserted-by":"crossref","DOI":"10.1096\/fba.2024-00151","article-title":"The role of amylin, a gut\u2013brain axis hormone, in metabolic and neurological disorders","volume":"7","author":"Muhammad","year":"2025","journal-title":"FASEB Bioadv."},{"key":"10.1016\/j.phrs.2026.108382_bib113","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.774050","article-title":"An overview of appetite-regulatory peptides in addiction processes; from bench to bed side","volume":"15","author":"Shevchouk","year":"2021","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.phrs.2026.108382_bib114","doi-asserted-by":"crossref","DOI":"10.1002\/cph4.70120","article-title":"Brain amylin signaling, feeding, and reward","volume":"16","author":"Mietlicki-Baase","year":"2026","journal-title":"Compr. Physiol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826002975?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826002975?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T10:56:10Z","timestamp":1789901770000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826002975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":114,"alternative-id":["S1043661826002975"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108382","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108382","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108382"}}